Related references
Note: Only part of the references are listed.Can ACEIs and ARBs be safely continued in COVID-19:- The Evidence is here at Last!
Uma Velupandian
HEART VIEWS (2021)
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
Jordana B. Cohen et al.
LANCET RESPIRATORY MEDICINE (2021)
Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2
Zhixin Liu et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis
Pan Luo et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults A Living Systematic Review
Katherine Mackey et al.
ANNALS OF INTERNAL MEDICINE (2020)
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Vanessa Monteil et al.
CELL (2020)
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Evangelos J. Giamarellos-Bourboulis et al.
CELL HOST & MICROBE (2020)
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
Daniel E. Freedberg et al.
GASTROENTEROLOGY (2020)
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
Yu-chen Cao et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection
Zou Xin et al.
FRONTIERS OF MEDICINE (2020)
Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19
John A. Jarcho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
Tobias Janowitz et al.
GUT (2020)
COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses
Muhammad Adnan Shereen et al.
JOURNAL OF ADVANCED RESEARCH (2020)
ACE2, Metformin, and COVID-19
Atul Malhotra et al.
ISCIENCE (2020)
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Miriam Merad et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Clinical trials on drug repositioning for COVID-19 treatment
Sandro G. Viveiros Rosa et al.
REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH (2020)
Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration
Chhinder P. Sodhi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2018)
Metformin improves obesity-associated inflammation by altering macrophages polarization
Yuanyuan Jing et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome
Akram Khan et al.
CRITICAL CARE (2017)
Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections
Zhen Zou et al.
NATURE COMMUNICATIONS (2014)
Angiotensin-Converting Enzyme 2: The First Decade
Nicola E. Clarke et al.
INTERNATIONAL JOURNAL OF HYPERTENSION (2012)
Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis
Jacquelyn J. Maher et al.
HEPATOLOGY (2008)
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
I Hamming et al.
JOURNAL OF PATHOLOGY (2004)
Angiotensin-converting enzyme 2 is an essential regulator of heart function
MA Crackower et al.
NATURE (2002)
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
C Vickers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
